Structured, doctor-led weight management combining GLP-1 injectable therapy (Wegovy, Mounjaro) with lifestyle, nutrition and exercise support — for adults with obesity, overweight and metabolic disease.
GLP-1 receptor agonists like Wegovy (semaglutide) and Mounjaro (tirzepatide) are highly effective medications for weight loss — but the medication alone is only part of the picture. Sustainable results come from combining the injection with a proper medical assessment, nutrition guidance, activity progression and regular follow-up.
At Inflexion we treat weight management as a medical condition: full history, physical examination, baseline labs (fasting glucose, HbA1c, lipid panel, liver and kidney function, thyroid), cardiovascular risk assessment, and a shared decision about whether GLP-1 therapy is the right fit — and if so, which drug.
Once-weekly subcutaneous injection. Approved for chronic weight management in adults with a BMI of ≥ 30, or ≥ 27 with weight-related comorbidities.
Once-weekly subcutaneous injection. A dual GLP-1 and GIP receptor agonist, giving greater average weight loss than semaglutide in head-to-head trials.
Full history, physical examination, weight and BMI trend, waist circumference, blood pressure, baseline labs (glucose, HbA1c, lipids, liver, kidney, thyroid) and cardiovascular risk.
We discuss Wegovy vs Mounjaro vs non-pharmacological programmes vs bariatric referral — matched to your goals, comorbidities and budget.
Weekly or fortnightly check-ins during dose titration to manage side effects, adjust the schedule and support the lifestyle plan.
Monthly follow-ups on the maintenance dose. Weight, waist and lab trends reviewed. Nutrition and exercise plans updated with our in-house physiotherapy team.
Structured taper and a maintenance plan to protect against weight regain when the medication is stepped down — the phase most weight-loss programmes underinvest in.
Book a medical assessment. We'll discuss whether Wegovy, Mounjaro or a non-medication path is the right fit for you.